Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents.

Bioconjug Chem

Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University. S- 751 85 Uppsala, Sweden.

Published: August 2003

Liposomes are of interest as drug delivery tools for therapy of cancer and infectious diseases. We investigated conjugation of epidermal growth factor, EGF, to liposomes using the micelle-transfer method. EGF was conjugated to the distal end of PEG-DSPE lipid molecules in a micellar solution and the EGF-PEG-DSPE lipids were then transferred to preformed liposomes, either empty or containing the DNA-binding compound, water soluble acridine, WSA. We found that the optimal transfer conditions were a 1-h incubation at 60 degrees C. The final conjugate, (125)I-EGF-liposome-WSA, contained approximately 5 mol % PEG, 10-15 EGF molecules at the liposome surface, and 10(4) to 10(5) encapsulated WSA molecules could be loaded. The conjugate was shown to have EGF-receptor-specific cellular binding in cultured human glioma cells.

Download full-text PDF

Source
http://dx.doi.org/10.1021/bc0100713DOI Listing

Publication Analysis

Top Keywords

development egf-conjugated
4
liposomes
4
egf-conjugated liposomes
4
liposomes targeted
4
targeted delivery
4
delivery boronated
4
boronated dna-binding
4
dna-binding agents
4
agents liposomes
4
liposomes interest
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!